Automatic quantitation of HIV-1 mediated cell-to-cell fusion with a digital image analysis system (DIAS): Application for rapid screening of HIV-1 fusion inhibitors

Journal of Virological Methods

Volumn 107, Issue 2, 2003, Pages 155-161

  Lu, Hong ^a   Zhao, Qian ^a   Xu, Zhikai ^a,b   Jiang, Shibo ^a  

^a NEW YORK BLOOD CENTER   (United States)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Automatic quantitation; Cell to cell fusion; gp41; HIV 1 fusion inhibitors

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ANIMAL CELL; ARTICLE; AUTOMATION; BIOASSAY; CELL FUSION; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMAGE ANALYSIS; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REGULATORY MECHANISM; SCREENING;

CELL FUSION; CELL LINE; COCULTURE TECHNIQUES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV-1; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MICROSCOPY, FLUORESCENCE; PEPTIDE FRAGMENTS; PROTEINS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0037292058     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-0934(02)00213-6     Document Type: Article

References (32)

1. Berger E.A. HIV entry and tropism: the chemokine receptor connection. AIDS. 11:1997;3-16.
2. Berger E.A., Murphy P.M., Farber J.M. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17:1999;657-700.
3. Berrey M.M., Schacker T., Collier A.C., Shea T., Brodie S.J., Mayers D., Coombs R., Krieger J., Chun T.W., Fauci A., Self S.G., Corey L. Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS. J. Infect. Dis. 183:2001;1466-1475.
4. Bieniasz P.D., Fridell R.A., Aramori I., Ferguson S.S., Caron M.G., Cullen B.R. HIV-1-induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR-5 co-receptor. EMBO J. 16:1997;2599-2609.
5. Chan D.C., Kim P.S. HIV entry and its inhibition. Cell. 93:1998;681-684.
6. Chan D.C., Fass D., Berger J.M., Kim P.S. Core structure of gp41 from the HIV envelope glycoprotein. Cell. 89:1997;263-273.
7. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:1984;27-55.
8. Cohen F.S., Melikyan G.B. Methodologies in the study of cell-cell fusion. Methods. 16:1998;215-226.
9. Debnath A.K., Radigan L., Jiang S. Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodecifiency virus type 1. J. Med. Chem. 42:1999;3203-3209.
10. Eckert D.M., Kim P.S. Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem. 70:2001;777-810.
11. Huerta L., Lamoyi E., Baez-Saldana A., Larralde C. Human immunodeficiency virus envelope-dependent cell-cell fusion: a quantitative fluorescence cytometric assay. Cytometry. 47:2002;100-106.
12. Jiang S., Debnath A.K. A salt bridge between an N-terminal coiled coil of gp41 and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity. Biochem. Biophys. Res. Commun. 270:2000;153-157.
13. Jiang S., Lin K., Strick N., Neurath A.R. HIV-1 inhibition by a peptide. Nature. 365:1993;113.
14. Jiang S., Lin K., Lu M. A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the HIV-1 envelope glycoprotein. J. Virol. 72:1998;10213-10217.
15. Jiang S., Radigan L., Zhang L. A convenient cell fusion assay for rapid screening for HIV entry inhibitors. Proc. SPIE. 3926:2000;212-219.
16. Jiang S., Zhao Q., Debnath A.K. Peptide and non-peptide HIV fusion inhibitors. Curr. Pharm. Des. 8:2002;563-580.
17. LaBranche C.C., Galasso G., Moore J.P., Bolognesi D.P., Hirsch M.S., Hammer S.M. HIV fusion and its inhibition. Antiviral Res. 50:2001;95-115.
18. Lu M., Kim P.S. A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein. J. Biomol. Struct. Dyn. 15:1997;465-471.
19. Moore J.P., Jameson B.A., Weiss R.A., Sattentau Q.J. The HIV-cell fusion reaction. Bentz J. Viral Fusion Mechanisms. 1993;233-289 CRC Press, Boca Raton.
20. Murakami T., Nakajima T., Koyanagi Y., Tachibana K., Fujii N., Tamamura H., Yoshida N., Waki M., Matsumoto A., Yoshie O., Kishimoto T., Yamamoto N., Nagasawa T. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J. Exp. Med. 186:1997;1389-1393.
21. Nakashima H., Masuda M., Murakami T., Koyanagi Y., Matsumoto A., Fujii N., Yamamoto N. Anti-human immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5,12, Lys-7]polyphemusin II): a possible inhibitor of virus-cell fusion. Antimicrob. Agents. Chemother. 36:1992;1249-1255.
22. Neurath A.R., Jiang S., Strick N., Lin K., Li Y.-Y., Debnath A.K. Bovine β-lactoglobulin modified by 3-hydroxyphthalic anhydride blocks the CD4 cell receptors for HIV-1. Nat. Med. 2:1996;230-234.
23. Nussbaum O., Broder C.C., Berger E.A. Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation. J. Virol. 68:1994;5411-5454.
24. Pine P.S., Weaver J.L., Oravecz T., Pall M., Ussery M., Aszalos A. A semiautomated fluorescence-based cell-to-cell fusion assay for gp120-gp41 and CD4 expressing cells. Exp. Cell Res. 240:1998;49-57.
25. Rocancourt D., Bonnerot C., Jouin H., Emerman M., Nicolas J.F. Activation of a beta-galactosidase recombinant provirus: application to titration of human immunodeficiency virus (HIV) and HIV-infected cells. J. Virol. 64:1990;2660-2668.
26. Sattentau Q.J., Moore J.P. The role of CD4 in HIV binding and entry. Philos. Trans. R. Soc. Lond. B Biol. Sci. 342:1993;59-66.
27. Shafer R.W., Vuitton D.A. Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1. Biomed. Pharmacother. 53:1999;73-86.
28. Sodroski J., Goh W.C., Rosen C., Campbell K., Haseltine W.A. Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity. Nature. 322:1986;470-474.
29. Sugiura W. Effect of introduction of highly active antiretroviral treatment and the changes in patterns of drug-resistant HIV-1 in Japan. J. Infect. Chemother. 7:2001;127-132.
30. Tang S.B., Levy J.A. Parameters involved in the cell fusion induced by HIV. AIDS. 4:1990;409-415.
31. Tozser J. HIV inhibitors: problems and reality. Ann. N.Y. Acad. Sci. 946:2001;145-159.
32. Wild C.T., Shugars D.C., Greenwell T.K., McDanal C.B., Matthews T.J. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. USA. 91:1994;9770-9774.